SAN FRANCISCO, CA, Day One Biopharmaceuticals announced a $130 million Series B financing from leading life sciences investors.
Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on accelerating therapies for children and adults with cancer, announced a $130 million Series B financing from leading life sciences investors.
The financing was led by RA Capital Management with participation from additional new investors Boxer Capital, BVF Partners L.P., Franklin Templeton, Janus Henderson Investors, Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., and Viking Global Investors. Existing investors Canaan, Access Biotechnology, and Atlas Venture also participated.
DAY101 is designed as a first-in-class, oral, highly-selective pan-RAF kinase inhibitor to target a key enzyme in the MAPK signaling pathway. Studies have shown DAY101 has high brain distribution and exposure in comparison to other MAPK pathway inhibitors, thus potentially benefiting patients with primary brain tumors or brain metastases of solid tumors. DAY101 is a type II RAF inhibitor that selectively inhibits both monomeric and dimeric RAF kinase.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about